The intricacies associated with cell therapy manufacturing have paved the way for novel automation technologies; owing to the introduction of technological advancements, the domain is likely to gain significant traction in the coming decade
LONDON, Sept. 13, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "Cell Therapy Manufacturing Market (5th Edition), 2022-2035" report to its list of offerings.
Over the years, several advanced and innovative automation tools and technologies have been developed; these have been demonstrated to hold the potential for significant reduction in the cost associated with the manufacturing of advanced therapy medicinal products (such as cell therapy manufacturing), thereby, making such products more affordable. One such emerging concept, namely GMP-In-A Box, offers several advantages, including increased throughput, decreased idle time between batch runs and reduced manual labor. However, the delicate nature of steps involved in the cell therapy manufacturing process is known to hinder the overall automation process. Further, the lack of specialized infrastructure and limited expertise available in this domain are some of the known challenges impacting the growth of this segment.
To order this 649 page report, which features 245+ figures and 285+ tables, please visit https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html
Key Market Insights
- The current market landscape features the presence of over 240 CDMOs and in-house players that are engaged in the manufacturing of cell therapies, across various scales of operation
- The cell therapy manufacturing market is primarily characterized by the presence of well-established players; majority of the manufacturers offer services for the development of immune cells
- Owing to the increasing demand for cell therapies, players have been expanding their manufacturing capabilities across different scales of operation; the US has emerged as the most prominent industry headquarters
- The number of partnerships inked in this domain demonstrates the growing interest of players in the cell therapy manufacturing market; majority of the deals have been done for the clinical manufacturing of T cell therapies
- In pursuit of obtaining a competitive edge and to eventually establish themselves as one-stop shops, stakeholders are actively consolidating their capabilities related to cell therapies through mergers and acquisitions
- Industry players are making extensive efforts to expand their existing capacities and capabilities for both clinical and commercial manufacturing of cell therapies
- Our proprietary total cost of ownership model suggests an informed estimate of direct and indirect expenses while setting up a contract manufacturing facility in different regions, over a span of 20 years
- Around 50% of the big pharma initiatives have been undertaken for the purpose of expanding their portfolio and capabilities through partnerships and collaborations; of these, 70% initiatives were undertaken post 2019
- Over 70 automation technologies are currently available for the manufacturing of cell therapies, sidestepping the involvement of manual efforts; this is likely to attract the interest of stakeholders in the cell therapy domain
- More than 80% of the current installed manufacturing capacity is presently being utilized for commercial scale manufacturing of cell therapies; maximum capacity is installed in facilities based in North America
- In 2035, close to 20% of the demand for cell therapies is likely to be generated by autologous T cell therapies for the treatment of patients suffering from various oncological disorders
- The global cell therapy manufacturing market is expected to grow at a CAGR of 12%, till 2035; T cell therapies and stem cell therapies capture more than 85% of the current market share
- The overall opportunity is expected to be well distributed across multiple segments; specifically, in the long term, commercial scale manufacturing is likely to drive the market's growth
For more information, please visit https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html
The financial opportunity associated with the cell therapy manufacturing market has been analyzed across the following segments:
- Type of Cell Therapy
- T cell therapies
- Dendritic cell therapies
- NK cell therapies
- Stem cell therapies
- Source of Cell
- Autologous
- Allogeneic
- Scale of Operation
- Clinical
- Commercial
- Purpose of Manufacturing
- In-house Manufacturing
- Contract Manufacturing
- Geographical Regions
- North America
- Europe
- Asia Pacific
- Rest of the World
The report also features inputs from eminent industry stakeholders, according to whom, the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with the setting-up of in-house expertise. The report includes detailed transcripts of discussions held with the following experts:
- Peter Coleman (Chief Executive Officer, RoslinCT)
- Dominic Clarke (Chief Technical Officer, Cell and Gene Therapy, Discovery Life Sciences)
- Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
- Gilles Devillers (General Manager, Bio Elpida)
- Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies)
- Arik Hasson (Executive VP Research and Development, Kadimastem)
- Fiona Bellot (Business Development Manager, RoslinCT)
- David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
- Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR)
- Arnaud Deladeriere (Manager, Business Development & Operations-cGMP Manufacturing Unit, C3i Center for Commercialization of Cancer Immunotherapy)
- Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
- Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, Yposkesi)
- Tim Oldham (Chief Executive Officer, Cell Therapies)
- Gerard MJ Bos (Chief Executive Officer, CiMaas)
The research includes profiles of key players (industry and non-industry; listed below), featuring a brief overview of the company / organization, along with details related to its manufacturing facilities, service portfolio, recent developments and an informed future outlook.
- AGC Biologics
- BioNTech Innovative Manufacturing Services
- Cell and Gene Therapy Catapult
- Cell Therapies
- Center for Cell and Gene Therapy, Baylor College of Medicine
- Center for Cell Manufacturing Ireland, National University of Ireland
- Charles River Laboratories
- Clinical Cell and Vaccine Production Facility, University of Pennsylvania
- FUJIFILM Cellular Dynamics
- Guy's and St. Thomas GMP Facility, Guy's Hospital
- KBI Biopharma
- Laboratory for Cell and Gene Medicine, Stanford University
- Lonza
- MEDINET
- Minaris Regenerative Medicine
- Molecular and Cellular Therapeutics, University of Minnesota
- Newcastle Cellular Therapies Facility, Newcastle University
- Nikon CeLL innovation
- Rayne Cell Therapy Suite, King's College London
- RoslinCT
- Scottish National Blood Transfusion Service, Scottish Centre of Regenerative Medicine
- Sydney Cell and Gene Therapy
- Thermofisher Scientific
- WuXi AppTec
Key Questions Answered
- What is the current, annual, global demand for cell-based therapies? How is the demand for such products likely to evolve over the next decade?
- What is the current, installed contract manufacturing capacity for cell therapies?
- What are the key parameters governing the price of cell therapies?
- What are the key recent developments (such as partnerships and expansions) that have been undertaken in the field of cell therapies?
- What kind of partnership models are commonly adopted by stakeholders engaged in the cell therapy manufacturing domain?
- What are the different types of initiatives undertaken by big pharma players for the manufacturing of cell therapies in the recent past?
- What are the different types of automated technology platforms that are available to be adopted for the development and manufacturing of cell therapies?
- Who are the key players (industry / non-industry) engaged in the manufacturing of cell-based therapies across the world?
- What is the estimated total capital expenditure required to set up a cell therapy manufacturing facility?
- What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to cell therapies?
- How is the current and future market opportunity likely to be distributed across various key market segments?
Table of Contents
1. Preface
2. Executive Summary
3. Introduction
4. Market Overview
5. Regulatory Landscape
6. Roadmaps for Overcoming Challenges
7. Automation Technologies for Cell Therapy Manufacturing
8. Profiles: Industry Players
9. Profiles: Non-Industry Players
10. Role of Non-Profit Organizations
11. Clinical Trial Analysis
12. Partnerships and Collaborations
13. Recent Expansions
14. Big Pharma Initiatives
15. Capacity Analysis
16. Demand Analysis
17. Cost Price Analysis
18. Make Versus Buy Decision Making Framework
19. Total Cost of Ownership
20. Market Sizing and Opportunity Analysis
21. Key Insights
22. SWOT Analysis
23. Concluding Remarks
24. Survey Analysis
25. Interview Transcripts
26. Appendix 1: Tabulated Data
27. Appendix 2: List of Companies and Organizations
For additional details, please visit https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html
You may also be interested in the following titles:
- Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (6th Edition): Industry Trends and Global Forecasts, 2022-2035
- Cell and Gene Therapy CRO Market (3rd Edition): Industry Trends and Global Forecasts, 2022-2035
- Gene Therapy Market (5th Edition): Industry Trends and Global Forecasts, 2022-2035
- TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
- TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
Contact:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
gaurav.chaudhary@rootsanalysis.com
Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg
View original content:
Voltar noticias em Inglês